

## Product Theater Schedule of Events

*Please note some presentations are requesting pre-registration. Those links are provided in the session listings below if applicable.*

### Tuesday, September 8, 2020

2–2:45 pm EST

*Explore YESCARTA® CAR T Therapy for Patients in Your Practice*

Kite Pharma

There is an unmet need in 3L R/R DLBCL as 73% of patients with R/R DLBCL do not respond to second or later lines of therapy. However, CAR T cell therapy has been approved for certain types of R/R DLBCL.

Those who attend this program can expect to gain insight into the CAR T treatment process, clinical data, including AE management, as well as the role that each provider plays during the patient journey.

*Intervening with Jakafi (ruxolitinib) to Achieve Durable Count Control: Real World Patient Case Discussion | Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea*

Incyte

Please join us on Tuesday, September 8, 2020 from 2:00 PM – 2:45 PM ET for a theater presentation hosted by Incyte Corporation. Incyte, a global biopharmaceutical company based in Wilmington, Delaware, is a company founded on the premise that investment in good science and the rigorous pursuit of R&D excellence can translate into new medicines that can positively affect patients' lives.

*Empowering Patients with Optune for GBM*

Novocure

Learn about Optune®, an FDA-approved device to treat patients with glioblastoma. At this ONS Learning Theater, an educational webcast sponsored by Novocure®, we'll review the current treatments available to patients with glioblastoma, including the efficacy and safety of Optune, and how to discuss Optune with patients. Learn from an expert and hear first-hand about a patient ambassador's treatment journey and the impact Optune has made on their life.

**INDICATIONS FOR USE** Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy. For the treatment of

recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. **IMPORTANT SAFETY INFORMATION** Contraindications Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure. Warnings and Precautions Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer). Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established. The most common ( $\geq 10\%$ ) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression. The most common ( $\geq 10\%$ ) adverse events seen with Optune monotherapy were medical device site reaction and headache. The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer. Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective. If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please see Optune Instructions for Use (IFU) for complete information regarding the device's indications, contraindications, warnings and precautions at [Optune.com/Safety](http://Optune.com/Safety)

*STIVARGA® (regorafenib) in Your Previously Treated Patients with Metastatic Colorectal Cancer (mCRC)*

Bayer

Bayer Sponsored No-CNE virtual clinical poster gallery regarding the treatment of patients with metastatic colorectal cancer with Denise O'Dea, APRN- BC and Oncology Nurse Educator, Bayer

3–3:45 pm EST

*Advancements In The Treatment Of Lung Cancer*

Genentech Tecentriq

**REGISTER HERE:** [www.geniersvp.com/SGEN30908](http://www.geniersvp.com/SGEN30908)

This program will present pivotal data and identify appropriate patient candidates from the IMpower133 and IMpower150 phase 3 clinical trials, as well as review important safety information.

*UDENYCA® (pegfilgrastim-cbqv) A Safe, Effective, and Affordable Alternative to Neulasta® (pegfilgrastim)*

**REGISTER HERE:** <http://bit.ly/coh00666>

Coherus Biosciences

Objectives:

- To review the clinical profile of UDENYCA®, including mechanism of action, efficacy, safety, indications, and dosing
- To examine the clinical development program for UDENYCA®, including key analytical, pharmacology, immunogenicity, and safety studies
- To support nurses in the management of patients on UDENYCA®

*Treatment of ES-SCLC and Unresectable Stage III NSCLC*

AstraZeneca (IMFINZI)

Beth Sandy, MSN, CRNP

Abramson Cancer Center, University of Pennsylvania  
Philadelphia, PA

**Thursday, September 10, 2020**

2–2:45 pm EST

*The Only Approved Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)*

Stemline Therapeutics

Join us for an overview of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a clinically aggressive and fatal hematologic malignancy that often presents with skin lesions. The program will aim to increase the understanding of BPDCN as well as educate on the efficacy, safety, dosing, and administration of the only approved treatment option for BPDCN.

*Fertility Preservation: Options for the Oncology Patient*

Walgreens/AllianceRx Walgreens Prime

Patients of childbearing age (and pediatric patients) who have been diagnosed with cancer may want to consider preserving their fertility and need to know their options. This presentation reviews the updated, currently approved and experimental treatments available for this patient population.

Objectives:

- Explain the emerging field of fertility preservation and oncofertility
- Identify some of the common concerns of individuals with a new cancer diagnosis when

considering their reproductive potential

- Describe the biological effects that cancer treatment can have on various aspects of reproduction
- List the various technologies available for fertility preservation and have a general understanding of their applications
- Describe how medical professionals can facilitate needs of patients who are interested in preserving fertility

*LONSURF® Oral Chemotherapy for Previously Treated Metastatic Colorectal, Gastric and Gastroesophageal Junction (GEJ) Cancers*

This presentation is sponsored by Taiho Oncology.

Please join us for a virtual learning hall presentation theater and overview of LONSURF® (trifluridine and tipiracil) hosted by Taiho Oncology. Cyndy Simonson, MS, APRN-BC, AOCN from Duke University Health System, will discuss LONSURF® and provide key information regarding this oral chemotherapy. We hope you will join us for this engaging event.

*A CDK 4 & 6 Inhibitor With Overall Survival Data for Women With HR+, HER2- Metastatic Breast Cancer, Including Those Likely To Do Worse © Lilly USA, LLC 2020. All rights reserved.*

Eli Lilly

Join us to learn more about a CDK 4 & 6 inhibitor with overall survival data for women with HR+, HER2- metastatic breast cancer, including those likely to do worse.

3–3:45 pm EST

*Treating Patients with Advanced Prostate Cancer: Metastatic and Non-Metastatic PC*

Janssen-ERLEADA

Haydee Kapin, DNP, ARNU, BC, AOCN from the University of Miami, Sylvester Comprehensive Cancer Center Miami, FL will be presenting a live session about "Treating Patients with Advanced Prostate Cancer: Metastatic and Non-Metastatic PC

*Selecting a First-in-Class Oral Therapy for Patients With HR+/HER2- Metastatic Breast Cancer*

Pfizer

Kimberly C. Podsada, RN, MSN, NP-C, OCN will speak on, "Selecting a First-in-Class Oral Therapy for Patients With HR+/HER2- Metastatic Breast Cancer."

*Managing Your Patients on BTK Inhibitor Therapy: Best Practices for Encouraging Patient Adherence*

AstraZeneca (CALQUENCE)

Provide an overview of CALQUENCE and review select clinical data supporting approval in CLL and MCL. Understand the safety profile for CALQUENCE, including the most commonly occurring adverse reactions. Review dosing and dose modifications for CALQUENCE. Support HCPs in encouraging adherence by providing proactive adverse reaction management and communication strategies.

*Supporting Patients With Metastatic NSCLC With Their Molecular Testing and Treatment Journey*  
AstraZeneca (TAGRISSO)

This presentation focuses on understanding the role of oncology nurses in guiding and supporting patients with metastatic EGFR mutation-positive NSCLC through diagnosis, molecular testing, and treatment. There will be additional discussion on the importance of obtaining and knowing all molecular test results prior to diagnosis. This presentation includes best practices and strategies to communicate with patients on how to effectively monitor for and manage the most common ARs with EGFR-TKI therapy to ensure optimal treatment benefit.

**Tuesday, September 15, 2020**

2–2:45 pm EST

*Eliminating Barriers and Transforming Specialty Pharmacy Care with Interoperability*

CVS Specialty

As a result of the pandemic, providers, many caring for patients virtually or operating with reduced staff, need ways to streamline operations without compromising patient care. Join Joel Helle, Vice President of CVS Specialty, to discuss the importance of interoperability and how harnessing its capabilities has eliminated barriers to treatment and enhanced provider efficiencies. We will also cover how real-time data exchange has positively transformed the timeliness of oncology interventions for patients utilizing specialty therapies.

3–3:45 pm EST

*Dosing and Adverse Reaction Management for LENVIMA® (lenvatinib)*

Eisai

Eisai Inc. is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases).

This promotional presentation is sponsored by Eisai Inc. The speaker is presenting the information contained herein on behalf of Eisai Inc. and the information being presented by the speaker is consistent with US Food and Drug Administration guidelines. This presentation is not continuing medical education.

*Clinical Considerations for Nurses When Administering DARZALEX FASPRO™*

Janssen Oncology (DARZALEX)

This presentation will discuss the following learning objectives:

- Explore the mechanism of action (MOA) of DARZALEX FASPRO™
- Evaluate the efficacy and safety data of DARZALEX FASPRO™
- Understand the administration of DARZALEX FASPRO™
- Dosing schedules, preparation, storage and handling, and injection technique
- Administration-related reactions management for DARZALEX FASPRO™
- Review DARZALEX FASPRO™ Important Safety Information and Summary

**Thursday, September 17, 2020**

2–2:45 pm EST

*Clinical Considerations for Nurses When Administering DARZALEX FASPRO™*

Janssen Oncology (DARZALEX)

This presentation will discuss the following learning objectives:

- Explore the mechanism of action (MOA) of DARZALEX FASPRO™
- Evaluate the efficacy and safety data of DARZALEX FASPRO™
- Understand the administration of DARZALEX FASPRO™
- Dosing schedules, preparation, storage and handling, and injection technique
- Administration-related reactions management for DARZALEX FASPRO™
- Review DARZALEX FASPRO™ Important Safety Information and Summary

*The Importance of PIK3CA Mutations in HR+/HER2- Advanced Breast Cancer*

Novartis

The Importance of PIK3CA Mutations in HR+/HER2- Advanced Breast Cancer presented by Linda Moors, PA-C

3–3:45 pm EST

*Important Treatment Considerations for Patients with Relapsed or Refractory Multiple Myeloma*

GlaxoSmithKline

Join a clinical educator as she provides an in-depth review of a treatment for patients with relapsed or refractory multiple myeloma. This presentation will discuss important prescribing information, clinical data, and address other commonly asked questions.